TRBC1 and angioimmunoblastic T-cell lymphoma: An ongoing phase I/II clinical trial (NCT03590574) is currently evaluating the safety and efficacy of AUTO4, a TRBC1CAR-T therapy for patients with TRBC1+ TCLs including PTCL, ALCL, and angioimmunoblastic T-cell lymphoma (AITL).